Navigation Links
The Treatment Landscape for Thyroid Carcinoma Will Change Dramatically Through 2021
Date:2/4/2013

BURLINGTON, Mass., Feb. 4, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2021, the treatment landscape for thyroid carcinoma will change dramatically in the United States and Europe due to the expected approval of several new therapies. In addition to Exelixis's Cometriq (cabozantinib) for advanced medullary thyroid carcinomas (MTC)—which was approved in the U.S. late last year—the other emerging agents in the thyroid carcinoma space are Bayer HealthCare/Onyx Pharmaceuticals' Nexavar (sorafenib), Eisai's lenvatinib, Genentech/Roche's Zelboraf (vemurafenib), GlaxoSmithKline's combination of dabrafenib and trametinib and OXiGENE's Zybrestat (fosbretabulin). A large focus of drug development has been on the radioiodine (RAI)-refractory, differentiated thyroid carcinoma (DTC) patient population.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

"These therapies will likely be high priced but will dramatically increase treatment options for RAI-refractory thyroid carcinoma patient populations for which there is no standard of care," said Decision Resources Analyst Gemma McConnell , Ph.D. 

According to Niche Markets and Rare Diseases: Thyroid Carcinoma, the overall incidence of thyroid carcinoma will increase over the next decade, driven by demographic change and more sensitive diagnostic procedures. In particular, the incidence of papillary thyroid carcinoma (PTC), which accounts for the vast majority of all diagnosed cases of thyroid carcinoma, will rise. In 2021, the number of incident cases of PTC will increase by approximately 23 percent, thereby contributing to an increase in the size of the drug-treatable population.

The report also finds that the opportunity for uptake of emerging agents developed for DTC will be constrained by small patient populations in the locally advanced or advanced disease setting. The majority of DTC cases are usually diagnosed early and have a good prognosis with current treatment of surgery, typically a total thyroidectomy, and RAI ablation therapy.

"Surgery and RAI therapy is the primary treatment approach for patients whose disease is considered resectable and the tumor is RAI-avid," Dr. McConnell said. "As long as a patient remains RAI-avid, RAI will remain the treatment of choice, constraining the opportunity for emerging therapies."

About Thyroid Carcinoma
Thyroid Carcinoma is offered as part of Decision Resources' Niche Markets and Rare Diseases service. Each report assesses opportunity in a select drug market across the United States, France, Germany, Italy, Spain and the United Kingdom. The report provides detailed coverage of patient populations, current therapies, unmet needs and emerging therapies, and includes primary research with country-specific thought leaders.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Arteriocyte Receives FDA Approval to Initiate Cellular Therapy Trial for Treatment of Thermal Burn Wounds in Wounded Warriors
2. B. Braun Smart Infusion Pump Technology Advances Patient Safety and Treatment Efficiency
3. FDA Advisory Committee Recommends Approval for Boehringer Ingelheims Olodaterol for Maintenance Treatment of COPD
4. The Treatment Landscape for Hepatocellular Carcinoma Will Change Dramatically Over the Next Ten Years Due to the Launch of New Therapies in the United States and EU5
5. Researchers at Scripps to Study Possible New Treatment for Parkinsons Disease
6. Foundation Venture Capital Group Invests In Start-Up Working to Reduce Side Effects of Parkinsons Treatment
7. US Vitamin Injections Discusses Bursitis Treatment with B12 Shots
8. Varian Equipment Selected to Equip New Cancer Center in Algeria and Enable More Advanced Radiotherapy Treatments for Patients
9. The Shift from Treatment to Prevention: A Drive towards Cutting Healthcare Costs
10. Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
11. NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Neuropsychiatric Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... New Zealand , May 24, 2016 ... and informatics solutions for the healthcare sector, has been named ... New Zealand Hi-Tech Awards 2016. Dr Bruce ... fantastic acknowledgement for our team.  It,s really good to be ... burden healthcare internationally. Our products are used in 35 countries ...
(Date:5/24/2016)... Los innovadores de COMBO[TM], ... introduce catéteres para la intervención de extremidades inferiores ... global especializada en el suministro de soluciones vasculares ... incluyendo productos para tratar la enfermedad arterial periférica. ... los dispositivos de primera entrada de la compañía ...
(Date:5/23/2016)... , May 23, 2016 ... Handling Equipment Market by Product (Wheelchair, Scooters, Medical ... (Bariatric Care, Critical Care, Wound), Accessories (Lifting, Transfer) ... to 2021", published by MarketsandMarkets, the patient handling ... Billion by 2021 at a CAGR of 10.5% ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... On May 23rd during the National ... Science® and international water advocate, was honored by Ashram, Inc. as the world’s foremost ... who knelt on the banks of the Nile to fill their red clay pots ...
(Date:5/26/2016)... ... May 26, 2016 , ... The introduction of our ... PROTECTION TO YOUR HEAD ™”. , “We are proud to introduce Meghan ... football front we have Brian Quick, wide receiver for Los Angeles who was a ...
(Date:5/26/2016)... ... 26, 2016 , ... Metcalf & Associates’ Maureen Metcalf ... experience in leading technology and human resources operations for health care, education, banking, ... be featured on Metcalf’s VoiceAmerica radio show , Innovative Leaders Driving Thriving ...
(Date:5/26/2016)... , ... May 26, 2016 , ... May 2016 – ... so central to popular cosmetic improvement efforts. Record numbers of clients now ask about ... prominent or pouty, says Kally Papantoniou, MD, of Advanced Dermatology P.C. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... is happy to announce the launch of its brand equity product, Brandvantage. ... to reflect the dynamic landscape of modern consumer decision-making. The proprietary framework ...
Breaking Medicine News(10 mins):